Global IVIS Imaging Systems Market Size By Type (Luminescence Imaging System, Fluorescence Imaging System), By Application (Hospitals, Veterinary Clinics), By Region, And Segment Forecasts, 2023 to 20...

The Global IVIS Imaging Systems Market was valued at USD 570 million in 2023 and is projected to reach USD 1.12 billion by 2031, growing at a CAGR of 8.8% during the forecast period from 2023 to 2031. IVIS (In Vivo Imaging Systems) are crucial tools in preclinical research and drug discovery, providing real-time, non-invasive imaging to monitor disease progression, treatment response, and biological processes in small animals. The market is witnessing robust growth due to increasing investments in biomedical research, rising demand for molecular imaging technologies, and advancements in imaging resolution and analytical capabilities.

Drivers:

1. Rising Preclinical Research Activities:

Increasing focus on drug development, oncology, and genetic research is boosting the demand for IVIS systems, as they provide real-time in vivo imaging critical for understanding disease mechanisms.

2. Technological Advancements in Imaging:

Advancements such as multi-modal imaging, higher spatial resolution, and software integration for data analysis are making IVIS systems more efficient and attractive to researchers.

3. Growing Adoption in Academic & Research Institutions:

The use of IVIS imaging systems is expanding in academic settings due to increasing grants and public-private research collaborations focused on disease modeling and therapy monitoring.

Restraints:

1. High Equipment and Maintenance Costs:

The initial investment and maintenance of IVIS systems can be substantial, limiting adoption among smaller research laboratories and institutions in developing regions.

2. Ethical Concerns and Regulatory Barriers:

Use of live animals for imaging raises ethical issues and regulatory hurdles, potentially affecting the deployment and expansion of such systems.

Opportunity:

1. Expanding Applications in Oncology and Neurology Research:

IVIS systems are gaining traction in cancer and brain research due to their capability to image tumor progression and neurological activity in real time.

2. Growth in Emerging Markets:

The increasing establishment of research centers and rising government initiatives for healthcare R&D in countries like India, China, and Brazil present lucrative market opportunities.

Market by System Type Insights:

Based on system type, the Bioluminescence Imaging Systems segment held the largest share in 2023, favored for its high sensitivity and non-invasive capabilities in preclinical animal studies. However, the Fluorescence Imaging Systems segment is expected to exhibit the fastest growth due to its broader application in multi-modal imaging, drug delivery, and real-time cellular monitoring.

Market by End-use Insights:

In terms of end use, Pharmaceutical & Biotechnology Companies emerged as the dominant segment in 2023, accounting for over 45% of the market share. These companies extensively use IVIS imaging in drug efficacy testing and preclinical validation. The Academic & Research Institutes segment is expected to witness significant growth due to increasing investment in translational and basic research globally.

Market by Regional Insights:

North America led the market in 2023, driven by high R&D expenditure, presence of major market players, and strong institutional support for preclinical research. Asia-Pacific is projected to be the fastest-growing region, fueled by rapid expansion in biotech industries, growing investment in life sciences, and government-backed initiatives to enhance research infrastructure.

Competitive Scenario:

Leading companies in the Global IVIS Imaging Systems Market include PerkinElmer Inc., Bruker Corporation, LI-COR Biosciences, Miltenyi Biotec, Thermo Fisher Scientific Inc., Mediso Ltd., and Photon etc. These firms are actively focusing on product innovation, expanding their imaging portfolios, and engaging in strategic partnerships to enhance their market position.

Key Developments:

In 2023, PerkinElmer Inc. launched a next-generation IVIS SpectrumCT 2 imaging system, integrating CT and optical imaging for improved anatomical resolution.

In 2024, Bruker Corporation introduced a high-sensitivity fluorescence imaging system optimized for oncology and immunology research.

In 2025, LI-COR Biosciences partnered with a major pharmaceutical firm to deploy IVIS imaging platforms in its oncology drug development pipeline.

Scope of Work – Global IVIS Imaging Systems Market

Report Metric Details

Market Size (2023) USD 570 million

Projected Market Size (2031) USD 1.12 billion

CAGR (2023–2031) 8.8%